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Abstract
Although epilepsy is associated with substantial role impairment, it is also highly comorbid with
other physical and mental disorders, making unclear the extent to which impairments associated
with epilepsy are actually due to comorbidities. This issue was explored in the National
Comorbidity Survey Replication (NCS-R), a nationally representative household survey of 5,692
US adults. Medically-recognized epilepsy was ascertained with self-report, comorbid physical
disorders with a chronic conditions checklist, and comorbid DSM-IV mental disorders with the
Composite International Diagnostic Interview (CIDI). Lifetime epilepsy prevalence was estimated
at 1.8%. Epilepsy was comorbid with numerous neurological and general medical conditions and
with a sporadic cluster of mental comorbidities (panic, PTSD, conduct disorder, and substance use
disorders). Although comorbid disorders explain part of the significant gross associations of
epilepsy with impairment, epilepsy remains significantly associated with work disability,
cognitive impairment, and days of role impairment after controlling comorbidities. The net
association of epilepsy with days of role impairment after controlling for comorbidities is
equivalent to an annualized 89.4 million excess role impairment days among US adults with
epilepsy, arguing that role impairment is a major component of the societal costs of epilepsy per se
rather than merely due to disorders comorbid with epilepsy. This estimated burden is likely
conservative as some parts of the effects of epilepsy are presumably mediated by secondary
comorbid disorders.
Keywords
epilepsy; seizure; epidemiology; comorbidity; role impairment; nosology
Address correspondence and reprint requests to Ronald C. Kessler, PhD, Department of Health Care Policy, Harvard Medical School,
180 Longwood Avenue, Boston, MA 02115, Tel. (617) 432–3587, Fax (617) 432–3588, Kessler@hcp.med.harvard.edu.
DISCLOSURE OF CONFLICTS OF INTEREST
Preparation of this report was supported, in part, by Ortho-McNeil Janssen Scientific Affairs, LLC. Dr. Kessler has served as a paid
consultant for GlaxoSmithKline Inc., Kaiser Permanente, Pfizer Inc., Sanofi-Aventis, Shire Pharmaceuticals, and Wyeth-Ayerst; has
served on advisory boards for Eli Lilly & Company and Wyeth-Ayerst; and has had research support for his epidemiological studies
from Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Ortho-McNeil
Pharmaceuticals Inc., Pfizer Inc., and Sanofi-Aventis. Dr. Stang is an employee of Johnson & Johnson Pharmaceuticals Research and
Development, who has a product for epilepsy. Mr. Lane and Dr. Shahly report no disclosures. We confirm that we have read the
Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.
NIH Public Access
Author Manuscript
Mol Psychiatry. Author manuscript; available in PMC 2013 January 01.
Published in final edited form as:
Mol Psychiatry. 2012 July ; 17(7): 748–758. doi:10.1038/mp.2011.56.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tINTRODUCTION
Epilepsy is among the most prevalent of the serious neurological disorders, affecting
roughly 50 million people worldwide1, 2 and 2.1–2.7 million Americans.3 Its burden
cascades beyond the immediate central nervous system dysfunction of the disorder per se to
a number of neurobehavioral impairments, role disabilities, and psychosocial
disadvantages.4 These are associated with substantial economic burdens documented in
studies showing that people with epilepsy have significantly lower family incomes than
other people; a pattern largely due to the un/underemployment of people with epilepsy.5
While estimates of the burden of epilepsy consistently increase in studies that include more
textured burden measures,6 these studies are limited in usually not adjusting for the wide
range of general medical and mental disorders known to be comorbid with epilepsy.7–10 An
evaluation of the extent to which estimates of the burden of epilepsy decrease when
comorbidities are controlled would be of considerable value given that targeted interventions
to reduce the adverse life course consequences of epilepsy should be guided by information
about important pathways that lead to these consequences. The current report addresses this
issue with data from the National Comorbidity Survey Replication (NCS-R),11 a national
epidemiological survey. We examine whether self-reported epilepsy is associated with
chronic physical and mental disorders and the extent to which the associations of epilepsy
with diverse measures of role impairment are explained by comorbid disorders.
MATERIALS AND METHODS
Sample
The NCS-R was a face-to-face household survey of English-speaking adults (ages 18+)
carried out between February 2001 and April 2003 in a multi-stage clustered area probability
sample of the US population. A detailed description of the NCS-R sample design is
presented elsewhere.12 The primary sampling areas (PSAs) [Census Metropolitan Statistical
Areas (MSAs) and non-MSA counties] were selected with stratification to guarantee
representativeness of the US population on a wide range of geographic and socio-
demographic characteristics. Recruitment of respondents within clustered probability
samples of households inside PSAs began with an advance letter and study fact brochure
followed by in-person interviewer visits to explain study aims and procedures, randomly
select a respondent, and obtain informed consent before administering the interview.
Respondents were paid $50 for participation. The response rate was 70.9%. A probability
sub-sample of non-respondents was then selected and paid $100 to complete a short non-
respondent survey. Recruitment and consent procedures were approved by the human
subjects committees of Harvard Medical School and the University of Michigan.
The survey was administered in two parts. Part I included a core diagnostic assessment
administered to all respondents (n = 9,282). Part II included questions about correlates and
additional disorders administered to all respondents who met lifetime criteria for any Part I
disorder plus a probability sub-sample of other Part I respondents (n = 5,692). The Part I
sample was weighted to adjust for differential probabilities of selection and minor non-
response bias detected in the non-respondent survey. The Part II sample, the focus of the
current report due to epilepsy being assessed in Part II, was then additionally weighted for
differential probabilities of selection into Part I depending on Part I disorders. A final weight
adjusted the Part II sample to match the 2000 census population on the cross-classification
of numerous geographic and socio-demographic variables to correct for minor residual
discrepancies between sample and population distributions on these variables. All analyses
employed these weights. More detailed information about NCS-R sampling, weighting, and
socio-demographic distributions is reported elsewhere.12
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tMeasures
Mental disorders—The majority of lifetime mental disorders were assessed in Part I. As
noted above, these assessments were used to differentially select respondents into Part II,
where assessments were made of additional mental disorders as well as of physical
disorders. All mental disorders were assessed with the fully-structured lay-administered
Composite International Diagnostic Interview (CIDI) Version 3.0.13 DSM-IV criteria were
used with diagnostic hierarchy and organic exclusion rules to make diagnoses of anxiety
(panic disorder, generalized anxiety disorder, phobias, PTSD, separation anxiety disorder),
mood (major depression, dysthymic disorder, bipolar disorder), disruptive behavior (ADHD,
oppositional-defiant disorder, conduct disorder, intermittent explosive disorder), and
substance (alcohol and drug abuse and dependence) disorders. Generally good concordance
was found between these DSM-IV/CIDI diagnoses and clinical diagnoses in blinded clinical
reappraisal interviews.14
Self-reported epilepsy—All Part II NCS-R respondents were asked: “Did a doctor or
other health professional ever tell you that you had epilepsy or seizures?” Virtually
identically worded questions have been used to ascertain cases in most other large-scale
epidemiological surveys of epilepsy.8, 15–18 Validation of responses to comparable questions
in other community surveys found that 76–89.5% of cases defined by a consensus diagnosis
of epilepsy were detected by self-report (sensitivity) and that 66–81.5% of self-reported
positives were confirmed by the consensus diagnosis (positive predictive value).19, 20
Comorbid physical disorders—Lifetime prevalence of common chronic physical
disorders was assessed with a Part II chronic conditions checklist21 based on the checklist in
the US National Health Interview Survey.22 Included were: cardiovascular (heart disease,
hypertension, history of heart attack, history of stroke), digestive (irritable bowel disorder,
ulcer), musculoskeletal (arthritis, chronic back/neck pain), pain (migraine, other chronic
headaches, other chronic pain conditions), respiratory (asthma, seasonal allergies, and other
lung conditions like COPD and TB), sensory (blindness, deafness, and serious hearing or
vision impairments), and other (cancer, diabetes) disorders. Such checklists, which are
widely used in community epidemiologic surveys, have been shown to yield more complete
and accurate information than open-ended health questions and to have moderate-high
agreement with independent medical records.23
Role Functioning—All Part II respondents were administered the World Health
Organization Disability Assessment Scale (WHO-DAS),24, 25 a multidimensional self-report
inventory of health-related limitations in role functioning during the past 30 days. The 8
WHO-DAS scales include three domains of basic activities of daily living (cognition,
mobility, self-care), two of instrumental activities of daily living (productive role
functioning, social role functioning), and three of societal response (stigma, discrimination,
and family burden). Scores on each WHO-DAS scale were normed to a theoretical 0–100
range. WHO-DAS scales have good internal consistency reliability and predictive validity.26
The WHO-DAS scale of productive role functioning included, among other items, three
questions of interest in themselves: number of days in the past 30 respondents were totally
unable to work or conduct their other daily activities because of health problems; and
number of days in the past 30 respondents were able to work but had to cut back either on
the quality or quantity of their work because of health problems. Responses to these
questions have shown good concordance with independent records of workplace sickness
absence in samples of workers.27 An overall measure of number of impaired performance
days was created by summing each day of total role loss (counting as a full day) and each
day of reduced work quantity or quality (each counting as half a day).
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tAnalysis methods
Cross-tabulations and bivariate logistic regression analyses were used to examine socio-
demographic correlates of epilepsy and comorbidities, including age, sex, race-ethnicity,
education, marital status, and employment status. Multivariate regression analysis was used
to examine associations of epilepsy with a dichotomous measure of work disability (logistic
regression) and with WHO-DAS scores (linear regression). All regression equations
controlled sequentially for socio-demographics, physical comorbidities, mental
comorbidities, and all comorbidities. Interaction tests were used to investigate whether
associations of epilepsy with the outcomes varied depending on the presence of comorbid
conditions. The Taylor series method28 implemented in SUDAAN Version 8.0.129 adjusted
results for the clustering and weighting of the NCS-R sample design. Logistic regression
coefficients and their standard errors were exponentiated for ease of interpretation and are
reported as odds-ratios (ORs) with 95% confidence intervals (CIs). Statistical significance
was consistently evaluated using design-based two-sided .05 level tests.
RESULTS
Prevalence and socio-demographic correlates
Epilepsy was estimated to have a lifetime prevalence of 1.8% (95% confidence interval:
1.4–2.2) and to be unrelated to age, sex, race-ethnicity, and education. (Results are not
reported, but are available on request.) Epilepsy was also estimated to be significantly more
common among the never married than the married and among those in the “other”
employed category (consisting of the unemployed, disabled, and those neither in the labor
force nor homemakers, retired, or students) compared to the employed.
Comorbidity with physical and mental disorders
Respondents with epilepsy were significantly more likely than others to report at least one of
the comorbid physical disorders assessed in the NCS-R (93.6% vs. 77.8%, p < .001), with an
OR of 4.2 (p < .001) after controlling for socio-demographic factors that could not be
consequences of epilepsy (age, sex, race-ethnicity). Epilepsy is positively related to all these
physical disorders, nearly half with statistically significant ORs (1.6–3.0 p = .032 - < .001),
including with stroke, hearing impairment, vision impairment, asthma, digestive disorders,
chronic non-migraine headaches, and arthritis. Interestingly, epilepsy is most strongly
related to high comorbidity, defined as having 4 or more comorbid physical disorders.
Specifically, 41.2% of respondents with epilepsy have high comorbidity compared to 20.2%
of other respondents (p < .001), while differences in the proportions of people with vs.
without epilepsy who have 1–3 comorbid physical disorders are much smaller and
inconsistent in sign.
As with physical comorbidities, respondents with epilepsy were significantly more likely
than other respondents to report at least one of the DSM-IV/CIDI mental disorders assessed
in the survey (67.9% vs. 47.0%, p = .011), with an OR of 2.1 (p = .011) after controlling for
age, sex, and race-ethnicity. (Table 2) Unlike physical disorders, though, the proportional
elevation in prevalence of mental disorders among people with vs. without epilepsy does not
vary systematically by number of comorbid disorders. Although epilepsy is positively
related to the vast majority of these mental disorders, only four associations are statistically
significant: with post-traumatic stress disorder, panic disorder, conduct disorder, and drug
abuse (OR = 1.8–3.3, p = .002–.043).
Labor force participation
The proportion of respondents in the labor force (i.e., either employed, self-employed,
looking for work, or disabled) who reported their employment status as “disabled” is nearly
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tfive times as high among those with than without epilepsy (33.1% vs. 7.0%, p < .001). The
OR between epilepsy and disability remains significant (p < .001) but decreases from 6.6 to
5.7 after controlling for age, sex, race-ethnicity, and education, to 4.1–5.0 after also
controlling for physical or mental disorders, and to 3.8 after controlling for both physical
and mental disorders. (Table 3) Given the earlier finding of high comorbidity between
epilepsy and other disorders, we also evaluated the significance of interactions between
epilepsy and number of comorbid physical and mental disorders in predicting disability, but
these interactions were not statistically significant (p = .19–.58).
WHO-DAS scores
Respondents with epilepsy reported elevated impairment in all 8 WHO-DAS domains.
(Table 4) Seven of the 8 unstandardized linear regression coefficients are significant (the
exception being self care), and in the range 1.4–15.8 (p = .001–.045) on the 0–100 response
scale. All these coefficients become smaller when controls are introduced for socio-
demographics and smaller yet when additional controls are included for comorbid physical
and mental disorders, with only the impaired cognition coefficient remaining significant
when all controls are added (2.4, p = .021). Interactions of epilepsy with number of
comorbid physical and mental disorders in predicting the 8 WHO-DAS scores are
insignificant in 15 of 16 cases (p = .15–.93). The exception is a negative interaction (p = .
018) between epilepsy and number of mental disorders predicting impairment in self-care.
Days out of role
Respondents with epilepsy reported a significantly higher mean number of days in the past
30 than other respondents when they were completely unable to conduct their daily activities
because of their health (2.0 vs. 0.6, p = .001) as well as significantly higher mean days of
reduced work quality (4.0 vs. 1.9, p = .003) and quantity (3.4 vs. 1.3, p = .003). Controlling
for socio-demographics, these differences are equivalent to unstandardized linear regression
coefficients of 1.2–1.8 (p = .005–.010). (Table 5) When we add controls for comorbid
disorders, the coefficients remain statistically significant for days out of role (0.8, p = .045)
and total days of role impairment (1.8, p = .022), but not days of reduced quality or quantity
(p = .07–.17). Based on the US Census population estimate of 232 million adults aged 18+
during the time of NCS-R data collection (www.census.gov/popest/national), the annualized
population projection from the final adjusted model is 89.4 million total days of role
impairment associated with epilepsy controlling for comorbid disorders. Interactions of
epilepsy with number of comorbid physical and mental disorders in predicting days out of
role measures are consistently insignificant (p = .46–.78).
DISCUSSION
The 1.8% lifetime prevalence estimate of self-reported medically recognized epilepsy in the
NCS-R is within the 1.2–2.0% range found in previous US general population surveys using
similar case definitions.8, 17, 30–33 Given the complexities of epilepsy diagnosis, such self-
reports are likely to be over-inclusive, capturing people with other paroxysmal or
neurological conditions in addition to epilepsy. Based on the positive predictive values of
69–81.5% in previous validation studies,19, 20 20–30% of NCS-R respondents classified
with epilepsy are likely to be false positives.
Our failure to detect significant associations of epilepsy with sex or race-ethnicity is
consistent with previous studies.8, 17, 33, 34 Although age-specific elevations have previously
been observed among children and the elderly, we did not expect them in the NCS-R owing
to the absence of children and the relatively small sub-sample of elderly in the sample.
Although we failed to confirm prior associations of epilepsy with low education,17, 35 a non-
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tsignificant trend was found. The findings that NCS-R respondents with epilepsy were much
more likely than others to remain unmarried and, if ever married, to divorce are also
consistent with previous surveys.33, 36, 37
Our finding of significant comorbidity between epilepsy and many other chronic physical
disorders is broadly consistent with other surveys in the US,7, 15, 33 Canada,9 and
Europe.38, 39 Specific patterns of comorbidity are also consistent with earlier studies,
confirming especially high comorbidities with neurological10, 38 (stroke, multiple sensory
impairments, headache) and functional or rheumatologic (asthma, digestive disorders, and
arthritis) disorders.31 Although causal pathways in these comorbidities are not fully
understood, chronic antiepileptic drug use has been implicated in comorbidity between
epilepsy and digestive disorders,18 while increased nicotine use has been implicated in
comorbidity between epilepsy and respiratory disorders.17, 31, 32, 38 Although it is not clear
why we found that comorbidity of epilepsy with physical disorders is largely due to high
comorbidity, this is a striking result that warrants further investigation.
The generally positive pattern of comorbidity between epilepsy and mental disorders in the
NCS-R is broadly consistent with previous epidemiological7, 8, 16–18 and clinical40–42
studies, as is the finding that comorbidity is stronger with physical than mental
disorders.38, 43 It is unclear, though, why significant associations of epilepsy with mental
disorders are limited to panic disorder, PTSD, and conduct disorder, as one would normally
expect associations with disorders to generalize to other strongly related disorders (i.e.,
phobias with panic disorder, major depression and generalized anxiety disorder with PTSD,
and all other behavior disorders with conduct disorder). This idiosyncratic NCS-R profile
raises the possibility that the significant ORs of epilepsy with panic disorder, PTSD, and
conduct disorder might reflect diagnostic confusions of a sort that has been documented in
clinical studies.44–46 The uniformly elevated associations of epilepsy with substance use
disorders, in comparison, are consistent with previous findings of decreased seizure
threshold related to alcohol47 and recreational drug10 use/withdrawal.
Our finding of a very strong unadjusted OR between epilepsy and disability (6.6) is broadly
consistent with previous studies.33, 48, 49 Even though this OR decreased substantially when
we controlled for comorbidity, the net OR of 3.8 remains very substantial, suggesting
indirectly that epilepsy has important adverse effects on employment independent of
comorbid disorders. The finding that epilepsy is positively associated with impairments in
all WHO-DAS domains is broadly consistent with previous findings of substantial
functional impairment in epilepsy.4, 6, 7 However, the finding that all but one of these
significant associations are explained by controls for comorbid disorders was unexpected,
especially in light of the subsequent finding of significant net associations of epilepsy with
days of role impairment. The finding of a significant net association of epilepsy impairment
in cognition is consistent with experimental and clinical evidence of deficits among
epileptics across multiple cognitive domains that have broad implications for psychological
adjustment and daily life.50
We are aware of no previous research that examined associations of epilepsy with days of
role impairment. The excess days out of role and of reduced work quantity and quality in the
gross analyses are substantial in comparison to estimates obtained in previous studies of
other chronic conditions.21 Although these gross associations are reduced substantially by
controls for comorbid disorders, the net association with overall days of role impairment
remains both statistically and substantively significant, with an annualized equivalent of
89.4 million days of role impairment associated with epilepsy in the US adult population.
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DAS scores and the significant net associations of epilepsy with disability and days of role
impairment is striking. This discrepancy might be related to the documented incongruence
between epilepsy patients’ objective recognition of the implications of their symptoms
(which would presumably be reflected in their reports of days of role impairment) and their
dampened subjective evaluation of these implications.51, 52 It is important to recognize in
this regard that the WHO-DAS scores are subjective ratings of severity of impairment.
Another indication that epilepsy is associated with a marked disjunctions between subjective
evaluation and objective personal circumstances is that while respondents with epilepsy
reported only modest decrements in social role functioning that were entirely explained by
comorbid conditions, these same respondents were objectively and significantly less likely
than others to have ever married and, if ever married, nearly twice as likely as others to be
divorced at the time of interview.
The fact that the net associations of epilepsy with the various outcomes considered here all
became smaller, and in the case of the WHO-DAS outcomes largely insignificant, when
comorbid disorders were controlled raises the possibility that causal effects of epilepsy on
these outcomes are mediated by comorbid disorders. However, there are two other plausible
scenarios that could account for the observed associations: that comorbid disorders cause
both epilepsy and impairments; and that unmeasured common causes led both to epilepsy
and comorbid disorders as well as to impairments. We have no way to adjudicate among
these different possibilities with the non-experimental cross-sectional NCS-R data. To the
extent that mediation is at work, though, interventions aimed at reducing the onset and
severity of secondary comorbid disorders might help reduce the impairments associated with
epilepsy even though substantial impairments associated with work disability and days out
of role remain even after controlling all comorbid disorders.
These conclusions should be interpreted in light of several limitations. The most obvious of
these is that epilepsy was assessed with self report. It is reassuring in this regard that recent
clinical reappraisal studies in community samples demonstrated good sensitivity and
positive predictive value of epilepsy self reports when compared to consensus medical
diagnoses.19, 20 Nonetheless, caution is needed in interpreting our results due to the
likelihood of misclassification of some cases. We also lacked data on specific seizure
parameters, although empirical support for associations between highly textured seizure
variables such as localization and lateralization and comorbidities remains equivocal.42, 53
Another limitation is that while the CIDI provides validated data on DSM-IV disorders
overall, it may overestimate comorbidity of mental disorders among people with epilepsy
due to the coarseness with which organic exclusions are assessed. The cross-sectional design
of the NCS-R and absence of data on age of onset are additional design limitations that
precluded the direct confirmation of temporal associations between epilepsy and comorbid
disorders. The small number of NCS-R respondents classified as having epilepsy (n = 135)
is another limitation, as it made it impossible to carry out sub-group analyses with adequate
statistical power. The large number of tests, finally, raises concerns about the possibility that
some of the significant net associations could be false positive findings. This might explain
the one significant interaction out of 16 between epilepsy and number of comorbid disorders
in predicting WHO-DAS scores.
Despite these limitations, the data reported here demonstrate clearly that epilepsy is
associated with numerous role impairments and that impairments associated with work
disability and days out of role remain significant in both statistical and substantive terms
even after adjusting statistically for a wide range of physical and mental comorbidities. To
the extent that epilepsy causes any of the comorbid disorders considered here and to the
extent that comorbid mental disorders are actually seizure epiphenomena, the true effects of
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tepilepsy on these role impairments are likely to be even greater larger than the net
associations documented here. Based on these results, it seems safe to conclude that role
impairments are major components of the societal costs of epilepsy rather than due entirely
to comorbid disorders.
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Table 3
The association (odds-ratio) between epilepsy and work disability among Part II NCS-R respondents in the
labor force (n = 4,332)1
Odds-Ratios2
Controls OR (95% CI)
None 6.6* (3.6–11.8)
Socio-demographics3 5.7* (3.4–9.5)
Socio-demographics3, physical disorders 4.1* (2.2–7.5)
Socio-demographics3, mental disorders 5.0* (3.0–8.3)
Socio-demographics3, physical and mental disorders 3.8* (2.2–6.7)
*
Significant at the .05 level, two-sided test
1
The prevalence (standard error) of disability is 33.1% (7.2) among respondents in the labor force with epilepsy and 7.0% (0.6) among other
respondents (t = 3.6, p < .01).
2
Based on a series of multivariate logistic regression models that predicted disability from epilepsy with controls for age, age squared, sex, and
race-ethnicity and subsequently controls either for physical disorders (a separate dummy variable for each disorder reported plus a linear term for
number of such disorders and a quadratic term for the square of the number of disorders), mental disorders (coded in the same was as for physical
disorders), or both physical and mental disorders. An additional model was estimated that added interactions of epilepsy with number of physical
and number of mental disorders, but these interactions were not statistically significant (χ22= 3.2, p = .20).
3
Age, age squared, sex, and race-ethnicity.
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